Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03703310 · ClinicalTrials.gov registry record · Phase 3
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
A Phase 3 study, sponsored by Sol-Gel Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 174
- Enrollment target
NCT03703310 is a Phase 3 study that has completed, run by Sol-Gel Technologies. The registered enrollment target is 174 participants.
The verdict
NCT03703310, a Phase 3 study, has completed, sponsored by Sol-Gel Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 174 participants
- Enrollment target
Study Summary
This is a global, multicenter, randomized, double-blind, stratified, vehicle-controlled study of the efficacy and safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult participants with Gorlin syndrome. Participants will be required to apply the investigational product for 12 months. The primary endpoint is a comparison between the two treatment arms of the number of new BCCs that develop over the 12 month period.
Interventions
- DRUG Patidegib Topical Gel, 2%
- DRUG Patidegib Topical Gel, Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2019-02-19 |
| Est. Completion | 2020-12-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03703310
The ClinicalTrials.gov registry entry for NCT03703310 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sol-Gel Technologies, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Patidegib Topical Gel, 2% is the first listed.
NCT03703310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03703310 about?
NCT03703310 is a clinical study titled "Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)". This is a global, multicenter, randomized, double-blind, stratified, vehicle-controlled study of the efficacy and safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult participants with Gorlin syndrome. Participants will be required to apply the investigational prod...
What is the current status of trial NCT03703310?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 174 participants. The study started on 2019-02-19. Estimated completion is 2020-12-28.
What interventions are being tested in trial NCT03703310?
The interventions under investigation include: Patidegib Topical Gel, 2% (DRUG), Patidegib Topical Gel, Vehicle (DRUG).
Who is sponsoring clinical trial NCT03703310?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.